Inovio Pharmaceuticals, Inc. (INO), a Biotechnology corporation, was a market gainer in the prior market session. Inovio Pharmaceuticals, Inc. (INO) stock opened the day for trading at $8.48 and closed the day at $8.44 with gains of +9.04%. This increase move beat the Nasdaq, a tech-heavy index, gain of +7.33% for the prior market day.

Inovio Pharmaceuticals, Inc. (INO) is focused on the Biotechnology sector. This market sector has seen some volatility from investors in recent trading sessions. Bullish investors of Inovio Pharmaceuticals, Inc. (INO) will be looking for positive upcoming earnings whereas bearish investors of Inovio Pharmaceuticals, Inc. (INO) will be looking for negative earnings. The last time Inovio Pharmaceuticals, Inc. (INO) had an earnings surprise was on Qtr Ending 12/19 when they reported -$0.32 compared to an estimate of -$0.23 which was a difference of -$0.09 resulting in a change of -39.13%. Current earnings estimates are to be released for Current Qtr 03/2020 on Inovio Pharmaceuticals, Inc. (INO) and out of 4 Wall Street estimates the average is saying -$0.23. The high estimate is saying -$0.20 whereas the low estimate is saying -$0.29 and the prior year Inovio Pharmaceuticals, Inc. (INO) announced earnings at -$0.30 a growth rate est. (year over year) of +23.33%.

The market performance of Inovio Pharmaceuticals, Inc. (INO) has varied recently. Year to date Inovio Pharmaceuticals, Inc. (INO)’s shares are up 155.76%. Over the past 12 weeks Inovio Pharmaceuticals, Inc. (INO) is up 154.99% and over the last 4 weeks Inovio Pharmaceuticals, Inc. (INO) is down -14.14%. Inovio Pharmaceuticals, Inc. (INO) current income statement shows revenue (ttm) of $4.11M. Gross Profit is $-82.01M. This puts the current EBITDA of Inovio Pharmaceuticals, Inc. (INO) at $-104.54M.

Wall street investors might also notice recent changes to stock analyst estimates for Inovio Pharmaceuticals, Inc. (INO). The stock is trading with an RSI (relative strength index) of 56.57 indicating Inovio Pharmaceuticals, Inc. (INO) is neither overbought nor oversold. Technically, INO’s short term support levels are around $7.64, $5.67 and $4.56 on the downside. INOs short term resistance levels are $18.90, $12.56 and $10.77 on the upside. The market cap of Inovio Pharmaceuticals, Inc. (INO) is $1.23B and institutions hold 30.20% of the stock. The outstanding share count stands at 141.64M while the short float (shares short) stands at 15.34%.

Research indicates that these estimate changes look to be directly correlated with short-term stock prices. The investors can look to capitalize on the basis of ranking. Inovio Pharmaceuticals, Inc. (INO) has short term rating of Neutral (-0.13), Intermediate rating of Bullish (0.45) and long-term rating of Bullish (0.32) giving Inovio Pharmaceuticals, Inc. (INO) an overall rating of Neutral (0.21).

The EPS growth this year on Inovio Pharmaceuticals, Inc. (INO) is decreased -15.40% and is expected to increase 1.30% next year. However, quarterly earnings (EPS) growth year over year on Inovio Pharmaceuticals, Inc. (INO) has decreased by -9.50% and quarterly revenue (Sales) growth year over year stands at -88.00%. Return on equity (ttm) is -283.10%.

Recent Developments:

2020-04-03 – Inovio Pharmaceuticals Filed Prospectus Supplement Pursuant To Sales Agreement For Offering Of Up To $150 Million.
2020-03-13 – Inovio Pharmaceuticals Files For Mixed Shelf Of Up To $400 Million.
2020-03-12 – Inovio Pharmaceuticals Reports Q4 Revenue Of $279,000.
2020-01-31 – Inovio Pharmaceuticals Files For Offer And Resale Of Up To 8.0 Mln Shares.
2020-01-30 – Inovio Collaborating With Beijing Advaccine To Advance Ino-4800 Vaccine Against New Coronavirus In China.

About Company:

Inovio Pharmaceuticals, Inc. , formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company’s electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake.



Source link